Leaderboards/Pharmacovigilance and Adverse Drug Reactions

Pharmacovigilance and Adverse Drug Reactions

Last updated July 7, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Yamin Shu
Peking University
2
Shenggeng Lin
Shanghai Jiao Tong University
3
Léa Hoisnard
Inserm
4
Mohammad A. Khaleel
Universiti Sains Malaysia
5
Anne M. Hause
Centers for Disease Control and Prevention
6
Yanchao Yin
Tongji Hospital
7
Huaqiao Jiang
Jinshan Hospital of Fudan University
8
Francisco Tsz Tsun Lai
Chinese University of Hong Kong
9
Annika Vestergaard Kvist
Aalborg University Hospital
10
Marion Robert
Université Grenoble Alpes

Rising Stars Papers

1
Early Safety Findings Among Persons Aged ≥60 Years Who Received a Respiratory Syncytial Virus Vaccine — United States, May 3, 2023–April 14, 2024
MMWR Morbidity and Mortality Weekly Report|2024
35 cit.
2
Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study
BMJ Open|2025
15 cit.
3
Risk of Gastrointestinal Perforation in Patients With Rheumatic Diseases Exposed to Janus Kinase Inhibitors Versus Adalimumab: A Nationwide Cohort Study
Arthritis & Rheumatology|2024
12 cit.
4
Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017–April 2024
Preventive Medicine Reports|2025
9 cit.
5
Rare but elevated incidence of hematological malignancy after clozapine use in schizophrenia: A population cohort study
PLoS Medicine|2024
7 cit.
6
Potential inappropriate medications and drug–drug interactions in adverse drug reactions in the elderly: a retrospective study in a pharmacovigilance database
Frontiers in Pharmacology|2025
7 cit.
7
Cost-effectiveness of sacituzumab tirumotecan versus chemotherapy for patients with metastatic triple-negative breast cancer in China
The Breast|2025
7 cit.
8
Clozapine use and risk of infections in patients with schizophrenia in Hong Kong: a population-based cohort study
The Lancet Psychiatry|2025
4 cit.
9
COVID-19 vaccine effectiveness against the Omicron variant of SARS-CoV-2 in multimorbidity: A territory-wide case-control study
iScience|2024
3 cit.
10
Effectiveness of post-COVID-19 primary care attendance in improving survival in very old patients with multimorbidity: a territory-wide target trial emulation
Family Medicine and Community Health|2024
3 cit.

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Charles Khouri
Inserm
2
Florence van Hunsel
University of Groningen
3
Emanuel Raschi
University of Bologna
4
Maribeth C. Lovegrove
Centers for Disease Control and Prevention
5
Birgitta Grundmark
Uppsala Monitoring Centre
6
Fei Guo
Shanghai Ship and Shipping Research Institute
7
Haohao Zhu
Guangdong Polytechnic Normal University
8
Amira Guirguis
University of Hertfordshire
9
Aaron J. Masino
Clemson University
10
Corinne M. Hohl
University of British Columbia

Emerging Leaders Papers

1
The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration
Drug Safety|2024
273 cit.
2
The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement
Drug Safety|2024
183 cit.
3
Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database
Journal of Affective Disorders|2023
108 cit.
4
Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands
Drug Safety|2022
58 cit.
5
The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database
European Archives of Psychiatry and Clinical Neuroscience|2023
58 cit.
6
Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis
European Neuropsychopharmacology|2024
58 cit.
7
COVID-19 vaccine reactogenicity – A cohort event monitoring study in the Netherlands using patient reported outcomes
Vaccine|2022
44 cit.
8
Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database
Journal of Affective Disorders|2023
43 cit.
9
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System
Targeted Oncology|2024
38 cit.
10
Drug-Induced Sexual Dysfunction: An Analysis of Reports to a National Pharmacovigilance Database
Drug Safety|2022
37 cit.

Current Senior Leaders

Established & currently active

Current Senior Leaders Researchers

1
Jeffrey K Aronson
University of Oxford
2
David W. Bates
Brigham and Women's Hospital
3
Matthew Hankins
Truven Health Analytics (United States)
4
Munir Pirmohamed
University of Liverpool
5
Gualtiero Palareti
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
6
Toine C. G. Egberts
Utrecht University
7
Graciela Gonzalez‐Hernandez
Cedars-Sinai Medical Center
8
Nigam H. Shah
Stanford University
9
Russ B. Altman
Stanford University
10
I. Ralph Edwards
Aston University

Current Senior Leaders Papers

1
Missing value estimation methods for DNA microarrays
Bioinformatics|2001
4.3k cit.
2
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
BMJ|2004
3.2k cit.
3
Adverse drug reactions: definitions, diagnosis, and management
The Lancet|2000
3k cit.
4
The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication
Psychology and Health|1999
2.4k cit.
5
Incidence of Adverse Drug Events and Potential Adverse Drug Events
JAMA|1995
2.1k cit.
6
Effect of Computerized Physician Order Entry and a Team Intervention on Prevention of Serious Medication Errors
JAMA|1998
2.1k cit.
7
Pharmacology and Management of the Vitamin K Antagonists
CHEST Journal|2008
2.1k cit.
8
The Incidence and Severity of Adverse Events Affecting Patients after Discharge from the Hospital
Annals of Internal Medicine|2003
1.9k cit.
9
Incidence and Preventability of Adverse Drug Events Among Older Persons in the Ambulatory Setting
JAMA|2003
1.7k cit.
10
Doxorubicin pathways
Pharmacogenetics and Genomics|2010
1.6k cit.

Reagents for Pharmacovigilance and Adverse Drug Reactions

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

🌟 All-Time

Most validated

Cell Signaling Technology

Apolipoprotein C-I (F9L6S) Rabbit Monoclonal Antibody

#92796$161,376
View Evidence →
Cell Signaling TechnologyEvidence 65

SMAD2/3 (D7G7) Rabbit Monoclonal Antibody (SignalFlex™ mFluor™ Red 780 Conjugate)

#75214$458
View Evidence →